US 12,012,404 B2
Pyrimidoheterocyclic compounds and application thereof
Yang Zhang, Shanghai (CN); Wentao Wu, Shanghai (CN); Jing Zhang, Shanghai (CN); Jikui Sun, Shanghai (CN); Yangyang Xu, Shanghai (CN); Zhijian Chen, Shanghai (CN); John Fenyu Jin, Shanghai (CN); and Shuhui Chen, Shanghai (CN)
Assigned to D3 Bio (Wuxi) Co., Ltd., Wuxi (CN)
Filed by D3 BIO (WUXI) CO., LTD., Wuxi Jiangsu (CN)
Filed on Sep. 22, 2023, as Appl. No. 18/473,147.
Application 18/473,147 is a continuation of application No. 17/905,973, previously published as PCT/CN2021/080278, filed on Mar. 11, 2021.
Claims priority of application No. 202010172140.2 (CN), filed on Mar. 12, 2020; application No. 202010323035.4 (CN), filed on Apr. 22, 2020; application No. 202010953203.8 (CN), filed on Sep. 11, 2020; and application No. 202011593642.9 (CN), filed on Dec. 29, 2020.
Prior Publication US 2024/0116934 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); C07D 491/052 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/04 (2013.01) [C07D 491/052 (2013.01); C07D 519/00 (2013.01)] 30 Claims
 
1. A compound of formula (III)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
T1 is selected from O and N;
R1 is selected from C6-10 aryl and 5- to 10-membered heteroaryl, wherein the C6-10 aryl and 5- to 10-membered heteroaryl are optionally substituted with 1, 2, 3, 4 or 5 Ra;
when T1 is O, R2 is not present;
when T1 is N, R2 is selected from H, C1-3 alkyl, —C(═O)—C1-3 alkyl and —S(═O)2—C1-3 alkyl, wherein the C1-3 alkyl, —C(═O)—C1-3 alkyl and —S(═O)2—C1-3 alkyl are optionally substituted with 1, 2 or 3 Rb;
R3 is C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Rc;
R4 is selected from H and C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Rd;
R5, R6 and R7 are each independently selected from H, F, Cl, Br, I and C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 F;
R8 is selected from H and CH3;
Ra is each independently selected from F, Cl, Br, I, OH, NH2, CN, C1-3 alkyl, C1-3 alkoxy, C2-3 alkynyl and C2-3 alkenyl, wherein the C1-3 alkyl, C1-3 alkoxy, C2-3 alkynyl and C2-3 alkenyl are optionally substituted with 1, 2 or 3 F;
Rb is each independently selected from F, Cl, Br, I, OH and NH2;
Rc is hexahydro-1H-pyrrolizinyl, wherein the hexahydro-1H-pyrrolizinyl is optionally substituted with 1, 2 or 3 R;
Rd is each independently selected from F, Cl, Br, I, OH, NH2 and CN; and
R is each independently selected from F, Cl, Br, OH, CN, C1-3 alkyl, C1-3 alkoxy and —C1-3 alkyl-O—C(═O)—C1-3 alkylamino;
provided that when R1 is naphthyl, the naphthyl is optionally substituted with F, Cl, Br, OH, NH2, CF3, CH2CH3 and —C≡CH, and R5, R6 and R7 are each independently H.